Hot Alert: Alcobra (NASDAQ:ADHD), (NASDAQ:JD), Enanta Pharmaceuticals (NASDAQ:ENTA), Tejon Ranch Co. (NYSE:TRC), Juno Therapeutics Inc. (NASDAQ:JUNO)

On Monday shares of Alcobra Ltd. (NASDAQ:ADHD) closed at $6.18. Alcobra Ltd. (NASDAQ:ADHD) on Wednesday reported a first-quarter loss of $5.2 million, after reporting a profit in the same period a year earlier. The Tel Aviv, Israel-based company said it had a loss of 26 cents per share., Inc. (NASDAQ:JD) in last trading activity moved up 2.13% to close at $34.46. Company weekly performance is 0.50% while its quarterly performance stands at 29.50%., Inc. (NASDAQ:JD) is -53.97% away from its 52 week high. JD.Com (NYSE:JD) had its price objective raised by Brean Capital from $35.00 to $37.00 in a research report released on Monday morning. Brean Capital currently has a buy rating on the stock.

On last trading day Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) moved up 1.05% to close at $35.67. Its volatility for the week is 5.61% while volatility for the month is 4.36%. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) monthly performance is -0.92%. On May 07, Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), reported financial results for its fiscal second quarter ended March 31, 2015. Cash, cash equivalents and short-term and long-term marketable securities totaled $226.8 million at March 31, 2015. Revenue for the three months ended March 31, 2015 was $57.4 million, compared to $2.2 million for the three months ended March 31, 2014.

Tejon Ranch Co. (NYSE:TRC) has 1.70% insider ownership while its institutional ownership stands at 76.40%. In last trading activity company’s stock closed at $24.48. Tejon Ranch Co. (NYSE:TRC) released the results of operations for the three months ended March 31, 2015, with the Company showing net income attributable to common stockholders of $1,617,000, or $0.08 per common share. That’s a $504,000 increase compared to net income attributable to common stockholders of $1,113,000, or $0.05 per common share, recorded for the same period in 2014.

On Monday shares of Juno Therapeutics Inc. (NASDAQ:JUNO) closed at $45.58. Juno Therapeutics (NASDAQ:JUNO) on Monday said it has acquired Stage Cell Therapeutics GmbH, a privately held biotechnology company based in Munich and Göttingen, Germany.

Leave a Reply

Your email address will not be published. Required fields are marked *